Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: A decision-analytic approach

Pharmacotherapy

Volumn 25, Issue 3, 2005, Pages 325-334

  Skrepnek, Grant H ^a   Ballard, Erin E ^b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Bone marrow transplantation; Chronic myelogenous leukemia; Imatinib; Markov model; Pharmacoeconomics

Indexed keywords

IMATINIB;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DONOR; DRUG COST; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MEDICAL DECISION MAKING; MEDLINE; MONTE CARLO METHOD; PROBABILITY; SENSITIVITY ANALYSIS;

ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HEALTH CARE COSTS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MARKOV CHAINS; MONTE CARLO METHOD; PIPERAZINES; PYRIMIDINES;

EID: 14544299196     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.3.325.61593     Document Type: Article

References (72)

1. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97:2229-35.
2. Redaelli A, Stephens JM, Laskin BL, et al. The burden and outcomes associated with four leukemias: AML, ALL, CLL and CML. Expert Rev Anticancer Ther 2003;3(3):311-29.
3. Garcia-Manero G, Faderl S, O'Brien S, et al. Chronic myelogenous leukemia: a review and update of therapeutic strategies. Cancer 2003;98(3):437-57.
4. Gordois A, Scuffham P, Warren E, et al. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia. Br J Cancer 2003;89(4):634-40.
5. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346(9):645-52.
6. Mauro MJ, O'Dwyer M, Heinrich MC, et al. ST1571: A paradigm of new agents for cancer therapeutics. J Clin Oncol 2002;20(1):325-34.
7. Mauro MJ, Druker BJ. Chronic myelogenous leukemia. Curr Opin Oncol 2001;13:3-7.
8. Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999;341(3):164-72.
9. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplant in treating the chronic phase of chronic myelogenous leukemia: developed for the American Society of Hematology. Blood 1999;94:1517-36.
10. Lee SJ, Anasetti C, Kuntz KM, et al. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 1998;92(11):4047-52.
11. Lee SJ, Kuntz KM, Horowitz MM, et al. Unrelated bone-marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 1997;127(12):1080-8.
12. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
13. Liberato NL, Quaglini S, Barosi G. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia. J Clin Oncol 1997;15(7):2673-82.
14. Goldman JM, Melo JV. Chronic myeloid leukemia: advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
15. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-7.
16. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038-42.
17. El-Zimaity MT, Kantarjian H, Talpaz M, et al. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004;125:187-95.
18. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004.
19. von Bubnoff N, Schneller F, Peschel C, et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to ST1571: a prospective study Lancet 2002;359:487-91.
20. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI-571, and they can pre-exist to the onset of treatment. Blood 2002;100:1014-18.
21. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
22. O'Dwyer ME, Drucker BJ. Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr Opin Oncol 2000;12:594-7.
23. Goldman JM. Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia. Lancet 2000;355:1031-2.
24. Geary CG. The story of chronic myeloid leukaemia. Br J Haematol 2000;110:2-11.
25. Azam M, Latek RR, Daley GQ. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-43.
26. Kattan MW, Inoue I, Giles FJ, et al. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia. Ann Intern Med 1996;125(7):541-8.
27. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study. Blood 2002;99(6):1928-37.
28. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 2002;99(10):3530-9.
29. Druker BJ, O'Brien SG, Cortes, J, et al. Chronic myelogenous leukemia. Hematol 2002;1:111-35.
30. Craddock C, Szydlo RM, Klein JP, et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood 2000;96(1):86-90.
31. Hehlmann R. Trial of IFN or STI571 before proceeding to allografting for CML? Leukemia 2000;14:1560-2.
32. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood 2000;95(7):2219-25.
33. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 1999;24:517-20.
34. Socie G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. N Engl J Med 1999;341(1):14-21.
35. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998;338(14):962-8.
36. Raiola AM, Van Lint MT, Valbonesi M, et al. Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. Bone Marrow Transplant 2003;31:687-93.
37. Cullis JO, Jiang YZ, Schwarer AP, et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992;79:1379-81.
38. Druker BJ. Chronic myeloid leukemia in the imatinib era. Semin Hematol 2003;40(suppl 2):1-3.
39. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol 2003;40(suppl 2):21-5.
40. O'Brien SG, Deininger MWN. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol 2003;40(suppl 2):26-30.
41. Hahn EA, Glendenning GA. Quality of life on imatinib. Semin Hematol 2003;40(suppl 2):31-6.
42. Goldman JM, Marin D, Olavarria E, et al. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol 2003;40(suppl 2):98-103.
43. Wassmann B, Klein SA, Scheuring U, et al. Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation. Bone Marrow Transplant 2001;28:721-4.
44. Muenning P. Designing and conducting cost-effectiveness analysis in medicine and health care. San Francisco: Jossey-Bass, 2002.
45. Barr JT, Schumacher GE. Decision analysis and pharmacoeconomic evaluations. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics, 3rd ed. Cincinnati: Harvey Whitney Books Company, 2005:175-210.
46. Rascati KL. Decision analysis techniques; practical aspects of using personal computers for decision analytic modeling. Drug Benefit Trends 1998;10:33-6.
47. Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998;13(4): 397-409.
48. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3(4):419-58.
49. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
50. Detsky AS, Naglie G, Krahn MD, et al. Primer on medical decision analysis. Med Decis Making 1997;17(2):123-59.
51. Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health 2002;5(2):82-97.
52. Heudebert GR, Marks R, Wilcox CM, et al. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997; 112:1078-86.
53. Nuijten MJC, Rutten F. The incorporation of potential confounding variables in Markov models. Pharmacoeconomics 2003;21(13):941-50.
54. Lawless JF, Fong DYT. State duration models in clinical and observational studies. Stat Med 1999;18:2365-76.
55. Sommer A, Zeger SL. On estimating efficacy from clinical trials. Stat Med 1991;10:45-51.
56. Vogelsang GB, Lee L, Bensen-Kennedy DM. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 2003;54:29-52.
57. Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002;62(6):879-89.
58. Antin JH. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med 2002;347(1):36-42.
59. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001;19(16):3685-91.
60. Chao NJ, Snyder DS, Jain M, et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biol Blood Marrow Transplant 2000;6(3):254-61.
61. Anonymous. Physicians' fee reference 2004, 21st ed. Milwaukee: Yale Wasserman, D.M.D. Medical Publishers, Ltd., 2004.
62. Anonymous. Physicians' fee and coding guide. Augusta, GA: Healthcare Consultants of America, Inc., 2004.
63. Cardinale V, ed. Drug topics red book. Montvale, NJ: Medical Economics Company, 2003.
64. National Comprehensive Cancer Network. Practice guidelines for the treatment of CML. Available from http://www.nccn.org/physician_gls/index.html. Accessed February 7, 2004.
65. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantation. Ann Intern Med 1994;120(2):143-58.
66. Skrepnek GH. Cost-effectiveness analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics, 3rd ed. Cincinnati: Harvey Whitney Books Company, 2005:83-116.
67. Black WC. The CE plane: a graphical representation of cost-effectiveness. Med Decis Making 1990;10:212-14.
68. Hochhaus A. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004;8(3):641-56.
69. Novartis Pharmaceuticals Corp. Gleevec (imatinib mesylate) package insert. East Hanover, NJ; 2004.
70. Deininger MWN, O'Brien SG, Ford JM, Drucker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21(8):1637-47.
71. Marin D, Marktel S, Bua M, et al. The use of imatinib (STI571) in chronic myeloid leukemia: some practical considerations. Haematologica 2002;87:979-88.
72. Crossman LC, O'Brien SG. Imatinib therapy in chronic myeloid leukemia. Hematol Oncol Clin N Am 2004;18(3): 605-17.